Gammacan Engages Global Markets Capital Group to Actively Pursue Strategic Alliances in the Blood, Plasma And IVIg Markets
February 03 2006 - 7:30AM
Business Wire
Specialists in Life Sciences Industry with Track Record of
Consummating Successful M&A and Corporate Transactions to
Assist Company in Achieving Strategic Objectives Gammacan
International (OTCBB:GCAN), a developer of immunotherapies for
cancer and other diseases, today announced that it has engaged
Global Markets Capital Corporation ("GMCG"), an independent
investment bank focused in the life sciences industry and
specializing in structuring and executing corporate transactions,
to assist the Company in achieving its strategic objective of
partnering with leaders in the blood, plasma and IVIg markets. "We
believe that the development of IVIg based products for the
treatment of metastatic cancer have advanced to a stage that
Gammacan is ready to explore various options of key synergistic
"partnerships" with IVIg manufacturers, plasma collectors, and
other players in the plasma industry," stated Vered Caplan, CEO.
Mark R. Saunders, President of Global Markets Capital Group, LLC,
stated, "Global Markets Capital Group is extremely pleased to work
with Gammacan, an emerging leader in the IVIg field. We look
forward to support Gammacan through strategic transactions that
will further the Company's efforts to develop and commercialize its
products and that will provide them with greater exposure in the
capital markets." About Global Markets Capital Group Global Markets
Capital Group, LLC (GMCG, LLC) is a New York based independent
investment banking firm with offices in Sydney, Australia that
provides innovative strategic advisory services and mergers and
acquisitions expertise globally to public and private life science
companies. Global Markets Capital Group currently represents a
number of the leading life science companies in the US and Europe,
as well as a large number of the leading publicly traded life
science companies in Australia. For further information on Global
Markets Capital Group visit www.globalmarketscapital.com. About
Gammacan: Gammacan is focusing on the commercialization of a
revolutionary anti-cancer immunotherapy that the Company believes
will be proven to be effective in reducing the metastatic spread of
a wide range of cancers. Gammacan's proposed treatment is based on
IVIg, a safe, relatively non-toxic human plasma-based product,
currently used to treat a variety of immune deficiencies and
autoimmune diseases. It works by strengthening the patient's immune
system. Many experts currently view immunotherapy as a future
alternative to today's standard chemotherapy. Approximately twenty
companies produce IVIg, and annual worldwide sales are currently in
excess of 50 metric tones with an estimated value in excess of 1.5
billion USD. IVIg is commonly used to treat certain autoimmune
diseases and blood disorders and to replace the antibodies in
people who are unable to produce them. For more information about
Gammacan visit www.gammacan.com or call the company's headquarters
in Givat Shmuel, Israel at 972 3 5774475. Safe Harbor Statement:
Statements in this document that are not purely historical are
forward-looking statements. Forward-looking statements in this
release include statements regarding: the commercialization of an
anti-cancer immunotherapy and the Company developing the boosting
of cancer patients' immune systems with IVIg into an effective
treatment. Actual outcomes and the Company's actual results could
differ materially from those in such forward-looking statements.
Factors that could cause actual results to differ materially
include risks and uncertainties such as the inability to finance
the planned development of the technology, inability to hire
appropriate staff to develop the technology, unforeseen technical
difficulties in developing the technology, inability to obtain
regulatory approval for human use, competitors' therapies proving
more effective, cheaper or otherwise preferable for consumers,
inability to market the product we produce, among other factors,
all of which could among other things, delay or prevent product
release or cause our company to fail. For further risk factors see
the risk factors associated with other early stage medical research
and development companies filed with the SEC on Edgar.
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Aug 2023 to Aug 2024